Nuvation Bio, Inc. (NUVB)
4.57
-0.13
(-2.77%)
USD |
NYSE |
Oct 23, 16:00
4.57
0.00 (0.00%)
After-Hours: 20:00
Nuvation Bio Enterprise Value : 1.354B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.354B |
| October 22, 2026 | 1.399B |
| October 21, 2026 | 1.452B |
| October 20, 2026 | 1.424B |
| October 19, 2026 | 1.323B |
| October 16, 2026 | 1.312B |
| October 15, 2026 | 1.417B |
| October 14, 2026 | 1.392B |
| October 13, 2026 | 1.406B |
| October 12, 2026 | 1.469B |
| October 09, 2026 | 1.504B |
| October 08, 2026 | 1.487B |
| October 07, 2026 | 1.455B |
| October 06, 2026 | 1.462B |
| October 05, 2026 | 1.487B |
| October 02, 2026 | 1.553B |
| October 01, 2026 | 1.700B |
| September 30, 2026 | 1.714B |
| September 29, 2026 | 1.721B |
| September 28, 2026 | 1.714B |
| September 25, 2026 | 1.763B |
| September 24, 2026 | 1.760B |
| September 23, 2026 | 1.753B |
| September 22, 2026 | 1.889B |
| September 21, 2026 | 1.879B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.802B |
| September 17, 2026 | 1.879B |
| September 16, 2026 | 1.777B |
| September 15, 2026 | 1.784B |
| September 14, 2026 | 1.833B |
| September 11, 2026 | 1.879B |
| September 10, 2026 | 1.952B |
| September 09, 2026 | 2.036B |
| September 08, 2026 | 2.068B |
| September 04, 2026 | 2.138B |
| September 03, 2026 | 2.124B |
| September 02, 2026 | 2.180B |
| September 01, 2026 | 2.078B |
| August 31, 2026 | 2.085B |
| August 28, 2026 | 2.085B |
| August 27, 2026 | 2.201B |
| August 26, 2026 | 2.190B |
| August 25, 2026 | 2.239B |
| August 24, 2026 | 2.120B |
| August 21, 2026 | 2.180B |
| August 20, 2026 | 2.145B |
| August 19, 2026 | 2.295B |
| August 18, 2026 | 2.190B |
| August 17, 2026 | 2.022B |
| August 14, 2026 | 1.931B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 662.44B |
| Pfizer Inc. | 222.94B |
| Bristol Myers Squibb Co. | 159.59B |
| Merck & Co., Inc. | 405.39B |
| EyePoint, Inc. | -123.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.84M |
| Revenue (Quarterly) | 31.69M |
| Total Expenses (Quarterly) | 94.53M |
| EPS Diluted (Quarterly) | -0.1802 |
| Gross Profit Margin (Quarterly) | 68.42% |
| Profit Margin (Quarterly) | -198.3% |
| Earnings Yield | -9.52% |
| Normalized Earnings Yield | -9.199 |